gout of foot The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum uric acid ...
PHILADELPHIA — Patients with gout who underwent an intensive treat-to-target regimen of monthly up-titration of urate-lowering therapy (ULT) to reach a target serum urate level were significantly more ...
SAN DIEGO, March 5, 2025 /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 ...
SAN DIEGO -- An investigational once-daily oral agent that inhibits urate transporter-1 (URAT1) as a means of forcing uric acid excretion showed good efficacy and safety in a pair of phase II trials ...
Management of a patient allergic to allopurinol can be considered a therapeutic challenge. This article highlights the diversity of medications that can be used to manage hyperuricemia during this ...
AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...
Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels. Bone erosion in patients with gout and tophi was associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results